IMI Cholesterol 1,2,3 Non-Invasive Skin Test To Debut In U.S. By Year-End
This article was originally published in The Gray Sheet
Johnson & Johnson's McNeil Consumer & Specialty Pharmaceuticals unit is on a shortlist of potential U.S. marketing partners for International Medical Innovations' Cholesterol 1,2,3 predictive test, which is expected to launch by year-end
You may also be interested in...
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.